Comparison · NCT02421172-9aaa6987
Period 1: CJM112 High Dose vs Period 1: Placebo: Clinical Responder Rate at Period 1: Week 16
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Period 1: CJM112 High Dose vs Period 1: Placebo: Clinical Responder Rate at Period 1: Week 16. Trial comparisons, record NCT02421172-9aaa6987. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02421172-9aaa6987
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.323 | 0.186 | 0.499 | wilson | |
| Risk in group 2 | 0.125 | 0.0497 | 0.281 | wilson | |
| Risk difference, group 1 minus group 2 | 0.198 | -0.00972 | 0.389 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.58 | 0.904 | 7.37 | log | |
| Odds ratio, group 1 over group 2 | 3.33 | 0.917 | 12.1 | log | |
| Number needed to treat, for one more participant with the outcome on Period 1: CJM112 High Dose than on Period 1: Placebo | 5.06 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Period 1: CJM112 High Dose | Period 1: CJM112 300mg subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses | 10 | 31 | OG000 |
| Group 2 | Period 1: Placebo | Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses | 4 | 32 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Clinical Responder Rate at Period 1: Week 16
- Description
Proportion of study participants achieving a clinical response in Hidradenitis Suppurativa - Physician Global Assessment (HS-PGA) score An HS-PGA responder in period 1 was a participant who had an initial HS-PGA score of at least 3 at baseline (Day 1, inclusion criterion) that decreased by at least 2 points. The six-point Physician Global Assessment (PGA) (scores range from 0-5) based on the number of HS lesions ranges from clear to very severe.
- Time frame
- Week 16
- Population
- PD analysis set 1 includes all patients who were CJM112-treated or placebo-treated in Period 1 with available PD data and no protocol deviations with relevant impact on PD data in Period 1.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
- NCT number
- NCT02421172
- Phases
- PHASE2
- Conditions
- Hidradenitis Suppurativa (Acne Inversa)
- Interventions
- CJM112, Placebo
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-05-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02421172?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02421172-9aaa6987